Glonghui, May 23 | Conoa-B (02162.HK) announced that recently, after review by the Drug Evaluation Center (“Drug Evaluation Center”) of the State Drug Administration, it was agreed to include spoximab injections in the priority review process for the treatment of chronic sinusitis with nasal polyps in accordance with the scope of priority review “(1) drugs in short supply, innovative drugs for the prevention and treatment of diseases such as major infectious diseases and rare diseases”.
According to reports, spochibimab (R&D code CM310) is an efficient, humanized antibody targeting the interleukin 4 receptor alpha subunit (IL-4Rα). It is the first domestically produced IL-4Rα antibody drug to be approved for clinical trials by the State Drug Administration. By targeting IL-4Rα, spoximab can double block the signal transduction of interleukin 4 (IL-4) and interleukin 13 (IL-13). IL-4 and IL-13 are two key cytokines that cause type II inflammation. Sproximab has shown good safety and encouraging efficacy in many previous clinical trials. As of the announcement date, the application for marketing licensing of spiqibizumab injections to treat moderate to severe atopic dermatitis and seasonal allergic rhinitis in adults has been accepted by the China Drug Administration.